[Study on premedication. (5). Clinical evaluation of cercine as a preanesthetic drug].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to I Sato.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Sato, Ichiei (Gunma University, Maebashi, Japan), and Susumu Mitsuhashi. Experimental salmonellosis. VII. In vitro transfer of cellular immunity by ribosomal fraction of mouse mononuclear phagocytes. J. Bacteriol. 90:1194-1199. 1965.-The mononuclear phagocytes (termed monocytes) of mice hyperimmunized with live vaccine of Salmonella enteritidis inhibited the intracellular growth of virulent strain 116-54 of S. enteritidis. Also, the monocytes withstood the degeneration of cells caused by the phagocytosis of bacteria in the absence of immune serum in the tissue culture medium, termed cellular immunity. When the nonimmune monocytes were incubated with the ribosomal fraction of immune monocytes, obtained from the abdominal cavity of mice hyperimmunized with live vaccine of S. enteritidis, they acquired cellular immunity, but the monocytes did not acquire immunity when ribosomal fractions from normal mouse monocytes or from the monocytes of mice immunized with killed vaccine of S. enteritidis were used. The transfer agent present in the ribosomal fraction of immune monocytes was inactivated by treatment with ribonuclease but not with deoxyribonuclease or with trypsin.
Wistar rats were injected once or repeatedly for 10 days with dichlorvos (DDVP, 5 mg kg-1), propoxur (10 mg kg-1), oxotremorine (0.1 mg kg-1) or atropine (5 mg kg-1). Animals were killed 20 min or 24 h after single or consecutive injections, respectively, for determinations of cholinergic activities and contractile responses to acetylcholine (ACh) of the jejunum. Single treatments: while DDVP and propoxur decreased acetylcholinesterase (AChE) activity, oxotremorine and atropine did not. Although DDVP, propoxur and oxotremorine increased levels of ACh, atropine decreased them. Contractile responses to ACh were enhanced by DDVP and reduced by oxotremorine and atropine. The Bmax value of binding of [3H]quinuclidinyl benzylate (QNB) to muscarinic ACh receptors was decreased by atropine. Consecutive treatments: DDVP and oxotremorine decreased AChE activity markedly and slightly, respectively. Although DDVP and oxotremorine increased levels of ACh, propoxur decreased them. Without affecting the contractile responses, DDVP caused a reduction and propoxur and atropine caused an increase in the Bmax value for binding of [3H]QNB. Both the contractile responses and the value of Bmax for binding of [3H]-QNB were decreased by oxotremorine. In summary, propoxur and DDVP showed similar effects mainly through their anticholinesterase properties in the case of single injection, but DDVP had similar effects to those of oxotremorine and propoxur had similar effects to those of atropine in the case of repeated injection.
Endothelin-1 (ET-1) has been reported to modulate bone metabolism both in vivo and in vitro. In the present study, we investigated the effect of ET-1 on inorganic phosphate (Pi) transport in osteoblast-like cells, which is now considered to be important for the initiation of bone matrix calcification. ET-1 time- and dose-dependently stimulated Na-dependent Pi transport in mouse calvaria-derived osteoblast-like MC3T3-E1 cells, and this effect was dependent on transcriptional and translational process. Kinetic analysis indicated that the change in Pi transport activity induced by ET-1 was due to alteration in the number of the Pi transporter. BQ123, a selective antagonist for ET(A) receptor, suppressed the ET-1-induced Pi transport, but BQ788, a selective antagonist for ET(B) receptor, had no effect. The inhibition of phosphoinositide hydrolysis by phospholipase C (PLC) partially attenuated the Pi transport by ET-1. Propranolol, which inhibits phosphatidic acid phosphohydrolase, also suppressed ET-1-induced Pi transport. On the contrary, indomethacin did not affect the stimulatory effect of Pi transport by ET-1. Calphostin C, a protein kinase C (PKC) inhibitor, significantly blunted the stimulatory effect of ET-1 on Pi transport. Combined effect of PMA and ET-1 on Pi transport was not additive. Pi transport induced by ET-1 was also suppressed in PKC down-regulated cells. In conclusion, the results of the present study indicate that in MC3T3-E1 osteoblast-like cells, ET-1 acting through ET receptor links to a stimulation of Pi transport via activation of PKC through both phosphoinositide and phosphatidylcholine hydrolyses.
Superovulatory responses in cattle are known to be highly variable. In the present study, a recombinant porcine follicle stimulating hormone (rpFSH) produced in baculovirus-insect cells was utilised to evaluate the role of this recombinant FSH in control of the ovulatory process. Immature hypophysectomised rats were implanted with oestrogen pellet (10 mg diethylstilbestrol) and then primed with pregnant mare serum gonadotropin (PMSG, 17.5 IU, sc). Fifty-two hours later, 100 microg rpFSH or saline was injected (sc) to induce ovulation. All rats that received rpFSH ovulated with about eight ova rat(-1), whereas none of the control animals did. Ovulation induced by rpFSH was associated with an increase in the ovarian activity and message levels of tissue-type plasminogen activator (tPA), a protease important in the preovulatory degradation of the follicle wall. Furthermore, addition of rpFSH to the cultured rat granulosa cells resulted in a significant increase in tPA enzyme activity. These results demonstrate that rpFSH produced in baculovirus-insect cells has biological potency in ovulation as well as gene expression of tPA, providing a large advantage of this massive expression system in the reproduction of domestic animals.
In order to evaluate whether canine herpesvirus (CHV) could be used as a live vector for the expression of heterologous immunogenes, we constructed a recombinant canine herpesvirus (CHV) expressing glycoprotein (G protein) of rabies virus (RV). The gene of G protein was inserted within the thymidine kinase gene of CHV YP11mu strain under the control of the human cytomegalovirus immediate early promoter. The G protein expressed by the recombinant CHV was processed and transported to the cell surface as in RV infected cells, and showed the same biological activities such as low pH dependent cell fusion and hemadsorption. The antigenic authenticity of the recombinant G protein was confirmed by a panel of monoclonal antibodies specific for G protein. Dogs inoculated intransally with the recombinant CHV produced higher titres of virus neutralizing antibodies against RV than those inoculated with a commercial, inactivated rabies vaccine. These results suggest that the CHV recombinant expressing G protein can be used as a vaccine to control canine rabies and that CHV may be useful as a vector to develop live recombinant against other infectious diseases in dogs.
The purpose of this study was to examine evidence for the presence of activated leukocytes in the fetal membranes from patients with preterm delivery. Polymorphonuclear leukocytes in fetal membranes from seven patients with preterm delivery (26-32 weeks of gestation) were analysed using transmission electron microscopy and ultrastructural enzyme-histochemistry for peroxidase and alkaline phosphatase. A large number of leukocytes accumulated in the fetal membranes from preterm deliveries. Phagosome, phagocytosis of cell debris, attachment of primary granules to the phagosomal membrane and cell surface projections were observed in fetal membrane leukocytes from preterm delivery but not in peripheral blood leukocytes. Peroxidase and alkaline phosphatase activity was demonstrated on the plasma membrane of the phagosomes. Morphological and enzyme-histochemical observation indicated that polymorphonuclear leukocytes in the fetal membrane in patients with preterm delivery were stimulated or activated. Such activated leukocytes may play a role in the pathophysiology or pathogenesis of preterm delivery.
The purpose of the present study was to examine morphological evidence for the presence of phagocytosing chorion laeve trophoblasts in fetal membranes from patients who had undergone chorioamnionitis-related preterm delivery. Chorion laeve trophoblasts from six patients, who underwent preterm delivery (28-34 weeks of gestation) complicated with chorioamnionitis, were analysed using transmission electron microscopy and ultrastructural enzyme-histochemistry for acid phosphatase, and compared with those from gestational age-matched chorioamnionitis-negative controls. Cytosomal cell projections, phagosomes, phagocytosis of degenerated cells and cell debris, attachment or fusion of lysosomes to the phagosomal membranes and phagosomal membranes positive for acid phosphatase staining were characteristically observed much more frequently in trophoblasts with chorioamnionitis than those without. The results indicated that chorion laeve trophoblasts in fetal membranes from patients having undergone chorioamnionitis-related preterm delivery underwent phagocytosis. Such phagocytosing trophoblasts may play a role in the pathophysiology or pathogenesis of infection-related preterm delivery.
The present study was designed to localize some important enzymes, such as adenosine diphospate-degrading enzyme (ADP-degrading enzyme) (plasma membrane enzyme), cytochrome c oxidase (mitochondrial enzyme) and glucose-6-phosphatase (endoplasmic reticulum enzyme), in placentae from patients with idiopathic fetal growth restriction (FGR) associated with absent end-diastolic flow velocity in the fetal umbilical artery. We compared these enzyme activities and their localization patterns to those in placentae both from pre-eclampsia with FGR and normal pregnancy with appropriate for their gestational age infants. In idiopathic FGR placentae, the intensity and localization patterns of these three enzymes did not differ from those seen in the placentae from normal pregnancy. Decreased ADP-degrading enzyme activity and cytochrome c oxidase negative mitochondria, which were characteristic features of pre-eclamptic trophoblasts, were absent from trophoblasts of the idiopathic FGR placentae. These observations indicated that enzyme-cytochemically detectable trophoblastic cell dysfunction may be absent in idiopathic FGR, or if present, there is less functional impairment of each trophoblast in this disease than in pre-eclampsia. Though both idiopathic FGR and pre-eclampsia lead to placental insufficiency, and finally to restricted fetal growth, a different mechanism and pathophysiology may work at the cellular and subcellular levels in these two diseases.
Explore the source record for details and available documents.
We demonstrated the subcellular localization of endothelial nitric oxide synthase (eNOS) in human placental terminal villous trophoblasts at near term period, and compared the distribution pattern with that in pre-eclamptic trophoblasts, using immunogold electron microscopy. Immunolabelling for eNOS was visible markedly in the syncytial microvilli and syncytial cytoplasm. Semiquantitative analysis showed that the concentration and the distribution pattern of gold particles for eNOS did not significantly differ between normal and pre-eclamptic placental trophoblasts. These results indicated that syncytiotrophoblastic microvilli and cytoplasm were the subcellular localization sites of syncytium-derived eNOS in terminal villi, and that there were no significant differences in this eNOS subcellular distribution pattern between normal and pre-eclamptic syncytiotrophoblasts in regard to immunohistochemically detectable eNOS.
We prepared a polyclonal antibody against recombinant human thymidylate synthase (TS) to evaluate its use in immunohistochemical analysis. Formalin-fixed, paraffin-embedded sections of specimens of cervical tissue were prepared from 35 patients with cervical cancer. The TS immunoreactivity was studied by employing the peroxidase-labeled antibody method with our prepared antibody. At the same time, the TS activity was determined with the 5-fluoro-2'-deoxyuridylate (FdUMP)-TS-binding assay in fresh-frozen specimens of these cervical cancers. We observed a positive correlation (r = 0.658) between the degree of TS immunoreactivity and the TS activity in the binding assay of 9 patients with grade 4 (strongly positive) TS immunoreactivity, while 7 patients (78%) exhibited a TS activity of 5 pmol/g tissue or greater. Nine patients with a TS immunoreactivity of grade 1 (negative to weakly positive) showed a TS activity <5 pmol/g tissue. The difference between the two groups was statistically significant (p < 0.01). TS expression was easily detected by the immunohistochemical technique which will allow the assessment of the relationship between TS activity and patient outcome.
An umbilical cord pseudocyst was detected in the 28th week of gestation in a fetus complicated with growth restriction and polyhydramnios. The combination of cord pseudocysts, growth restriction, and polyhydramnios prompted us to perform a detailed ultrasonographic examination (gray scale and three-dimensional), which revealed the presence of micrognathia, overlapping fingers, and congenital heart defects, features characteristic of trisomy 18. Karyotyping confirmed a diagnosis of trisomy 18. After spontaneous labor onset, the infant was delivered at 31 weeks of gestation, and died soon after delivery. An umbilical cord pseudocyst is a good marker for the prenatal detection of trisomy 18.
We determined the serum levels of macrophage colony-stimulating factor (M-CSF) in 441 women with gynecologic diseases to evaluate its role as a marker for gynecologic malignancy. Serum M-CSF levels were above the normal baseline level of 1,056 U/ml in 64% (56/88) of patients with ovarian cancer, 27% (16/60) of those with cervical cancer, and 25% (15/61) of those with endometrial cancer. M-CSF was significantly elevated in the serum of patients with advanced as compared with early stage cancer (stage I) of the ovary (p < 0.01), cervix (p < 0.05), and endometrium (p < 0.05). Only 5.6% of the patients with benign ovarian tumors and 7.0% of those with endometrial cysts had serum levels of M-CSF that exceeded 1,056 U/ml. M-CSF was localized in the glandular epithelial cells as well as in the stromal macrophages and the endothelial cells of the ovarian cancers. M-CSF thus appeared to be a marker with high specificity for ovarian cancer.
We attempted to assess the clinical utility of squamous cell carcinoma antigen (SCC) for detecting squamous cell carcinoma arising in mature cystic teratoma of the ovary. SCC in serum from 16 patients with this malignancy and from 56 patients with mature cystic teratoma without malignancy was measured using radioimmunoassay. Serum SCC levels exceeded the cut-off of 2.0 ng/ml in 9 (56%) of the 16 patients with malignancy. This rate was significantly higher than that in the patients with nonmalignant mature cystic teratoma (9 to 56, 16%; p < 0.01). The positive rate for SCC was as low as 30% for stage I cancer. All cases in which the tumor size was > 500 cm3 had a positive response for SCC, whereas all other cases had a negative response (p < 0.001). SCC is useful as a tumor marker for this malignancy. However, the serum SCC level depends on the tumor volume, so it may not be suitable for early detection of small tumors.
We studied the production of macrophage colony-stimulating factor (M-CSF) and the expression of c-fms mRNA, an M-CSF receptor, in four human ovarian cancer cell lines. All four cell lines expressed c-fms mRNA while three secreted M-CSF into the culture medium. The exogenous administration of M-CSF caused no significant enhancement of cellular proliferation in any cell line. Interestingly, the proliferation of KK cells was not affected by anti-M-CSF antibody. These results, taken together with the fact that ovarian cancer cells simultaneously produce M-CSF and c-fms, suggest that an autocrine mechanism may modulate cellular proliferation.
We evaluated the efficacy of S-1 as a new oral antitumor agent in ovarian cancer-bearing nude rats. This drug consists of tegafur, 5-chloro-2,4-dihydroxypyridine, and oxonic acid in a molar ratio of 1:0.4:1.S-1 was given alone or in combination with cisplatin. When administered alone at a daily dose of 20 mg/ kg, S-1 produced a significant inhibition of tumor growth [inhibition rate (IR) 89%] in the treated versus the control animals (p < 0.05). The effects of S-1 resembled those of cisplatin-treated groups. The consecutive daily administration of S-1, 20 mg/kg, combined with cisplatin, 1 mg/kg, markedly inhibited cell growth (IR 99%), a significant difference relative to cisplatin alone (p < 0.05). The daily administration of S-1 combined with low-dose cisplatin induced tumor regression with a low toxicity.